Pettit DL, Perlman S, Malinow R (1994)
Protocol 3: metabolic health optimization Goal: Reduce liver fat, improve insulin sensitivity, address metabolic syndrome Tirzepatide approach: Standard escalation to 10 mg Produces moderate liver fat reduction Significant HbA1c improvements (if diabetic) Meaningful but not maximal metabolic improvements Retatrutide approach: Escalation to 8-12 mg 86% of patients achieved normal liver fat at 12 mg Superior metabolic marker improvements across all measures Glucagon component directly targets hepatic lipid metabolism If metabolic health is your primary goal rather than the number on the scale, the retatrutide dosage chart offers something tirzepatide fundamentally cannot: direct glucagon-mediated liver fat reduction
According to an older 2013 review of research, they may have lipotropic effects in rodents: Very limited research exists on the efficacy, safety, and lipotropic properties of the ingredients used in these injections for weight loss
A Clinical Trial about a Food Supplement Containing -Lipoic Acid on Oxidative Stress Markers in Type 2 Diabetic Patients. International journal of molecular sciences vol
In rodent studies, BPC-157 has been shown to accelerate tendon and ligament repair, safeguard the gut lining, and reduce inflammation, according to the Journal of Physiology and Pharmacology review, 2018